While our division is a small part of the company today, we have a tremendous opportunity in front of us. We are not only creating an exciting new medical business with significant growth potential, we are also helping improve the quality of healthcare.

 

Our product, the InSpectra™ StO2 Tissue Oxygenation Monitor, provides clinicians with a fast, objective means to assess a patient’s perfusion status. By monitoring how well tissue and organs are being perfused with oxygen, clinicians can make timely and appropriate treatment decisions.

 

Current methods for assessing perfusion are limited. Blood tests, such as base deficit and lactate are snapshots of the past. Blood pressure and heart rate are indirect and highly variable. Other measurements, such as ScvO2, require insertion of a central venous catheter. In contrast, our device is noninvasive and provides a direct and continuous measurement.

 

Our initial focus has been on the trauma market where assessing perfusion status is critical in treating patients suffering from a traumatic injury. If inadequate perfusion is not detected and treated, it can lead to shock and put patients at risk. Clinical study results, and a growing amount of clinician experience, support the use of InSpectra StO2 as a sensitive, real-time indicator of perfusion status in trauma patients.

 

But the opportunity doesn’t stop there. Because perfusion is fundamental to organ and tissue health, there is growing interest from clinicians in other areas, such as emergency transport, emergency departments, operating rooms and intensive care units. The market opportunity is estimated at over 30 million patients annually.

 

Our long-term goal is for our device to be the standard of care for measuring tissue perfusion. In working toward that goal, we intend to help clinicians reduce risks, lower costs and save lives.